Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New ...
Specialised Therapeutics receives exclusive license to commercialize rigosertib in Australia and New Zealand Onconova to be eligible to receive up to US $30.4 million in clinical, regulatory, and sales-based milestones and tiered double-digit royalties …